Generex Biotechnology steigt und steigt (Seite 302)
eröffnet am 08.02.06 09:38:31 von
neuester Beitrag 29.10.22 19:06:08 von
neuester Beitrag 29.10.22 19:06:08 von
Beiträge: 4.745
ID: 1.038.703
ID: 1.038.703
Aufrufe heute: 0
Gesamt: 422.734
Gesamt: 422.734
Aktive User: 0
ISIN: US3714853013 · WKN: A2DL9M
0,0470
EUR
+0,86 %
+0,0004 EUR
Letzter Kurs 21.02.22 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 0,9300 | +54,46 | |
| 2,4700 | +33,51 | |
| 1,5000 | +22,45 | |
| 3,4600 | +17,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6205 | -11,36 | |
| 1,2600 | -11,89 | |
| 0,9970 | -14,60 | |
| 0,8501 | -17,47 | |
| 5,0550 | -22,71 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 23.071.846 von smiley13 am 26.07.06 21:23:59Du glaubst doch nicht,das die Big Player das zulassen werden.Die müssen sehr wenig investieren um so eine Firma wegzublasen!
Antwort auf Beitrag Nr.: 23.069.817 von heinzballer am 26.07.06 20:14:16Schätze eher, dass wir morgen die 1,65 $ sehen, rein technische Reaktion 
und wenn die durchbrochen wird, träumen wir wieder von 2 $
Auf jedenfall entfernen wir uns von deinem 0,5 $
und wenn die durchbrochen wird, träumen wir wieder von 2 $
Auf jedenfall entfernen wir uns von deinem 0,5 $
Antwort auf Beitrag Nr.: 23.068.970 von sneake am 26.07.06 19:19:58-technische Reaktion-news bedingt! Könnte heute mal mit 2% + schließen. Das war,s aber auch schon wieder!
NEWS !!!!!!!!!!!!!!!!!!!!
Generex Biotechnology Clinical Data Presented at Controlled Release Society Annual Meeting
Wednesday July 26, 10:45 am ET
TORONTO--(MARKET WIRE)--Jul 26, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), a leader in the area of buccal drug delivery, announced today that it made two poster presentations of clinical data at the 33rd Annual Meeting & Exposition of the Controlled Release Society in Vienna, Austria, July 22 - 26, 2006. The data relates to Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, and to Generex Metformin Gum, a proprietary alternative delivery format for metformin under development by Generex in collaboration with Fertin Pharma A/S.
"The invitation to present our most recent data at this important international scientific symposium in the drug delivery sector is a gratifying recognition of our successes to date," said Anna Gluskin, the Company's President & Chief Executive Officer.
The Controlled Release Society (CRS) (www.controlledreleasesociety.org) is an international organization which serves 3,000 members from more than 50 countries. Two-thirds of the CRS membership represents industry and one-third represents academia and government. The CRS is a multi-disciplinary, international organization dedicated to improving quality of life by advancing science, technology, and education in the field of controlled delivery of bioactive substances.
The first poster, entitled "Transfer From Short-Acting Insulin to Generex Oral-lyn(TM) at Lunchtime in 27 Juvenile Type-1 Diabetes Mellitus Patients: Importance of Diabetes Monitoring During the Stabilization Phase of a 6-Month Study," was authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President -- Medical Affairs.
The poster reports observations during the initial phase of an on-going long-term study, taking place at the Institute of Endocrinology IEMYR in Quito, Ecuador with Dr. Guevara as principal investigator, performed in 24 adolescent and 5 young adult patients with Type-1 diabetes mellitus receiving subcutaneously (s.c.) injected twice daily (BID) glargine insulin as basal therapy and s.c. regular insulin before meals. The principal aim of the study is to compare the effects of replacing the lunchtime dose of s.c. regular insulin with Generex Oral-lyn given as a split dose before and after lunch.
Since the study participants were referred to the institute in various degrees of metabolic control, it was necessary to stabilize them using standard therapy before replacement of the s.c. injection by Generex Oral-lyn at lunchtime. For this purpose, in addition to s.c. BID basal therapy and pre-prandial s.c. insulin, participants received enhanced nutritional advice and intense glucose monitoring for 21 days prior to replacement of the s.c. injected insulin by Generex Oral-lyn. The poster reports that the participants were metabolically stabilized in 21 days as documented by improvements in 6-point glucose daily profiles and protein glycation parameters that, in addition, showed correlation.
The second poster, entitled "The Generex Metformin Gum: An Alternative Method for Delivery of Biguanides," was authored by Drs. Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President -- Medical Affairs.
The poster reports the results of a clinical trial designed to compare pharmacokinetic profiles of metformin (used for the treatment of Type-2 diabetes mellitus in adults and children) administered by both the traditional manner (tablets) and by an alternative presentation (the Generex Metformin Gum product) that can be chewed thereby delivering metformin into the human body by way of the buccal cavity (i.e., the mouth).
The conclusion of the study is that the Generex Metformin Gum displays a pharmacokinetic profile similar to that of the metformin tablets and therefore shows promise as an alternative method of delivering metformin. The Generex Metformin Gum presentation should avoid the significant adverse gastrointestinal side-effects often accompanying the use of metformin tablets thereby improving patient compliance. In addition, Generex Metformin Gum is expected to be an ideal companion product for the Company's oral insulin spray product, Generex Oral-lyn(TM). Generex Oral-lyn is designed to offer a safe, simple, fast, effective, flexible, and familiar alternative to subcutaneous injections of prandial insulin.
Generex Biotechnology Clinical Data Presented at Controlled Release Society Annual Meeting
Wednesday July 26, 10:45 am ET
TORONTO--(MARKET WIRE)--Jul 26, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), a leader in the area of buccal drug delivery, announced today that it made two poster presentations of clinical data at the 33rd Annual Meeting & Exposition of the Controlled Release Society in Vienna, Austria, July 22 - 26, 2006. The data relates to Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, and to Generex Metformin Gum, a proprietary alternative delivery format for metformin under development by Generex in collaboration with Fertin Pharma A/S.
"The invitation to present our most recent data at this important international scientific symposium in the drug delivery sector is a gratifying recognition of our successes to date," said Anna Gluskin, the Company's President & Chief Executive Officer.
The Controlled Release Society (CRS) (www.controlledreleasesociety.org) is an international organization which serves 3,000 members from more than 50 countries. Two-thirds of the CRS membership represents industry and one-third represents academia and government. The CRS is a multi-disciplinary, international organization dedicated to improving quality of life by advancing science, technology, and education in the field of controlled delivery of bioactive substances.
The first poster, entitled "Transfer From Short-Acting Insulin to Generex Oral-lyn(TM) at Lunchtime in 27 Juvenile Type-1 Diabetes Mellitus Patients: Importance of Diabetes Monitoring During the Stabilization Phase of a 6-Month Study," was authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President -- Medical Affairs.
The poster reports observations during the initial phase of an on-going long-term study, taking place at the Institute of Endocrinology IEMYR in Quito, Ecuador with Dr. Guevara as principal investigator, performed in 24 adolescent and 5 young adult patients with Type-1 diabetes mellitus receiving subcutaneously (s.c.) injected twice daily (BID) glargine insulin as basal therapy and s.c. regular insulin before meals. The principal aim of the study is to compare the effects of replacing the lunchtime dose of s.c. regular insulin with Generex Oral-lyn given as a split dose before and after lunch.
Since the study participants were referred to the institute in various degrees of metabolic control, it was necessary to stabilize them using standard therapy before replacement of the s.c. injection by Generex Oral-lyn at lunchtime. For this purpose, in addition to s.c. BID basal therapy and pre-prandial s.c. insulin, participants received enhanced nutritional advice and intense glucose monitoring for 21 days prior to replacement of the s.c. injected insulin by Generex Oral-lyn. The poster reports that the participants were metabolically stabilized in 21 days as documented by improvements in 6-point glucose daily profiles and protein glycation parameters that, in addition, showed correlation.
The second poster, entitled "The Generex Metformin Gum: An Alternative Method for Delivery of Biguanides," was authored by Drs. Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President -- Medical Affairs.
The poster reports the results of a clinical trial designed to compare pharmacokinetic profiles of metformin (used for the treatment of Type-2 diabetes mellitus in adults and children) administered by both the traditional manner (tablets) and by an alternative presentation (the Generex Metformin Gum product) that can be chewed thereby delivering metformin into the human body by way of the buccal cavity (i.e., the mouth).
The conclusion of the study is that the Generex Metformin Gum displays a pharmacokinetic profile similar to that of the metformin tablets and therefore shows promise as an alternative method of delivering metformin. The Generex Metformin Gum presentation should avoid the significant adverse gastrointestinal side-effects often accompanying the use of metformin tablets thereby improving patient compliance. In addition, Generex Metformin Gum is expected to be an ideal companion product for the Company's oral insulin spray product, Generex Oral-lyn(TM). Generex Oral-lyn is designed to offer a safe, simple, fast, effective, flexible, and familiar alternative to subcutaneous injections of prandial insulin.
Mann, seid ihr alle schlau !
Worauf begründet ihr denn euer Fachwissen bzgl. des Delistings etc.? Wer kann von uns schon einen fairen Kurs für die Aktie nennen? Für mich ist das alles basherei.
Zugegeben, es gibt wenig Meldungen. Das bedeutet aber nicht, dass die Aktie bald abgehen kann wie Schmidtz´s Katze ! Einfach jetzt günstig kaufen und ne Weile warten. Nicht so viel zocken. Hin und Her macht Taschen leer !
Gruß liftboi
Worauf begründet ihr denn euer Fachwissen bzgl. des Delistings etc.? Wer kann von uns schon einen fairen Kurs für die Aktie nennen? Für mich ist das alles basherei.
Zugegeben, es gibt wenig Meldungen. Das bedeutet aber nicht, dass die Aktie bald abgehen kann wie Schmidtz´s Katze ! Einfach jetzt günstig kaufen und ne Weile warten. Nicht so viel zocken. Hin und Her macht Taschen leer !
Gruß liftboi
Trading Spotlight
Antwort auf Beitrag Nr.: 23.041.907 von bonscott_80 am 25.07.06 16:51:06Und das wird gar nicht so lange dauern!
Antwort auf Beitrag Nr.: 23.039.768 von Format_C am 25.07.06 15:10:53Platz schon, aber vielleicht wenig Zeit.
Wie ich letztens sagte, formatiert sich der Wert.
Ich halte 50 cent auch für realistisch. Von dort kam der Wert ja auch vor nicht allzu langer Zeit.
Wenn der Wert noch wesentlich weiter sinkt, und an der Nasdaq ein Delisting erfolgt, dann ist alles aus.
Wie ich letztens sagte, formatiert sich der Wert.
Ich halte 50 cent auch für realistisch. Von dort kam der Wert ja auch vor nicht allzu langer Zeit.
Wenn der Wert noch wesentlich weiter sinkt, und an der Nasdaq ein Delisting erfolgt, dann ist alles aus.
Antwort auf Beitrag Nr.: 23.034.667 von Gismo37 am 25.07.06 10:00:13Oder sich warm anzuziehen 
Bißchen Platz is noch bis 50 Cent
Bißchen Platz is noch bis 50 Cent
Denke es wird zeit sich einzudecken. Meine meinung
Antwort auf Beitrag Nr.: 22.908.725 von dermitdemstock am 22.07.06 19:06:55diese verwässerung hört sich aber gar nicht gut an !
Durchsuchen
